EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting erythroid progenitor cells for cancer immunotherapy

Su-Ran Li, Zhi-Zhong Wu, Hai-Jun Yu, Zhi-Jun Sun iD

International Journal of Cancer · 2024-12 · 155 (11) · 1928-1938

DOI: 10.1002/ijc.35102 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Cancer, online erschienen am 22.07.2024. Verfasst von Su-Ran Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Lab…. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Tumor Microenvironment, Erythroid Precursor Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, The Interdisciplinary Innovative Foundation of Wuhan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy, especially immune checkpoint blockade therapy, represents a major milestone in the history of cancer therapy. However, the current response rate to immunotherapy among cancer patients must be improved; thus, new strategies for sensitizing patients to immunotherapy are urgently needed. Erythroid progenitor cells (EPCs), a population of immature erythroid cells, exert potent immunosuppressive functions. As a newly recognized immunosuppressive population, EPCs have not yet been effectively targeted. In this review, we summarize the immunoregulatory mechanisms of EPCs, especially for CD45 + EPCs. Moreover, in view of the regulatory effects of EPCs on the tumor microenvironment, we propose the concept of EPC‐immunity, present existing strategies for targeting EPCs, and discuss the challenges encountered in both basic research and clinical applications. In particular, the impact of existing cancer treatments on EPCs is discussed, laying the foundation for combination therapies. The aim of this review is to provide new avenues for improving the efficacy of cancer immunotherapy by targeting EPCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyTumor MicroenvironmentErythroid Precursor CellsHumansAnimalsLeukocyte Common Antigens

Stichwörter der Autor:innen

cancererythroid progenitor cellsextramedullary hematopoiesisimmunotherapytargeting strategies

Substanzen

Leukocyte Common Antigens

Autor:innen und Institutionen

  • State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Frontier Sci…
  • Department of Radiation and Medical Oncology, Hubei Provincial Clinical Research Center for Cancer, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, P. R. China.

ORCID-Profile: Zhi-Jun Sun

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • The Interdisciplinary Innovative Foundation of Wuhan University
  • The Fundamental Research Funds for the Central Universities

Zitieren

APA

Li, S. R., Wu, Z. Z., Yu, H. J., & Sun, Z. J. (2024). Targeting erythroid progenitor cells for cancer immunotherapy. International Journal of Cancer, 155(11), 1928-1938. https://doi.org/10.1002/ijc.35102

Vancouver

Li SR, Wu ZZ, Yu HJ, Sun ZJ. Targeting erythroid progenitor cells for cancer immunotherapy. International Journal of Cancer. 2024;155(11):1928-1938. doi:10.1002/ijc.35102

BibTeX
@article{Li2024,
  author = {Li, Su-Ran and Wu, Zhi-Zhong and Yu, Hai-Jun and Sun, Zhi-Jun},
  title = {Targeting erythroid progenitor cells for cancer immunotherapy},
  journal = {International Journal of Cancer},
  year = {2024},
  volume = {155},
  number = {11},
  pages = {1928--1938},
  doi = {10.1002/ijc.35102}
}
Kostenlos starten →